Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept treatment in patients with primary Sjögren’s syndrome
2009-015558-40Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- Dec 2009
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abatacept in primary Sjögren's syndrome, sponsored by University Medical Center Groningen. Primary endpoint: Stimulated whole saliva flow rate at 24 weeks. Started Dec 2009; status: completed.
02
Drugs
abatacept
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on 2009-015558-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015558-40.